Consistently, we found that YTHDF1 was decreased whereas AKR1C1 was increased by IHC in 100% (6/6) NSCLC patients resistant to platinum based neoadjuvant chemotherapy, whose lung cancer progression were examined by computerized tomography (CT) scan. The gene discussed is YTHDF1; the disease is non-small cell lung carcinoma.